The forecasted data for the sold production of antisera and vaccines in Sweden shows a consistent growth from 2023 to 2027. Starting at €1.508 billion in 2023, there is a projected increase to €1.8621 billion by 2027. This equates to a year-on-year growth: 6.05% from 2023 to 2024, 5.60% from 2024 to 2025, 5.18% from 2025 to 2026, and finally, 4.84% from 2026 to 2027. The Compound Annual Growth Rate (CAGR) over this 5-year period is approximately 5.42%, indicating a steady upward trajectory in the production value of these crucial healthcare products.
Looking ahead, key trends to monitor include advancements in vaccine technology, global health challenges such as emerging infectious diseases, and regulatory changes affecting production and distribution. Additionally, the increasing focus on personalized medicine and biologics could influence the demand and development strategies for antisera and vaccines in Sweden.
